BioCentury | Mar 16, 2009
Company News

Oncolin cancer news

...of a preclinical portfolio of anticancer therapeutics. Oncolin will retain a 25% stake in Intertech. Oncolin...
...due to current market conditions and will allow it to continue to focus on energy. Oncolin Therapeutics Inc....
BioCentury | Jul 21, 2008
Company News

Oncolin scientific advisory board update

Oncolin Therapeutics Inc. (OTCBB:OCOL), Houston, Texas Business: Cancer Appointed: Waldemar Priebe, professor of medicinal chemistry at the University of Texas M. D. Anderson Cancer Center, as chairman WIR Staff cancer...
BioCentury | Jun 30, 2008
Company News

Oncolin scientific advisory board update

Oncolin Therapeutics Inc. (OTCBB:OCOL), Houston, Texas Business: Cancer Appointed: Daniel Von Hoff, CSO of US Oncology and Scottsdale Clinical Research Institute and a member of the National Cancer Advisory Board WIR Staff cancer...
BioCentury | Jun 16, 2008
Company News

Oncolin, University of Texas M. D. Anderson Cancer Center deal

...Oncolin will have exclusive rights to any resulting new patents. Further terms were not disclosed. Oncolin Therapeutics Inc....
BioCentury | May 12, 2008
Company News

Oncolin scientific advisory board update

Oncolin Therapeutics Inc. (OTCBB:OCOL), Houston, Texas Business: Cancer Appointed: Randall Johnson, an industry consultant WIR Staff...
BioCentury | Apr 21, 2008
Clinical News

Oncolin preclinical data

...improvements that were similar to Temodar monotherapy. Schering-Plough Corp. (NYSE:SGP, Kenilworth, N.J.) markets Temodar temozolomide. Oncolin Therapeutics Inc....
BioCentury | Mar 10, 2008
Company News

Oncolin scientific advisory board update

Oncolin Therapeutics Inc. (OTCBB:ELHI), Houston, Texas Business: Cancer Appointed: Sandra Silberman WIR Staff...
Items per page:
1 - 7 of 7
BioCentury | Mar 16, 2009
Company News

Oncolin cancer news

...of a preclinical portfolio of anticancer therapeutics. Oncolin will retain a 25% stake in Intertech. Oncolin...
...due to current market conditions and will allow it to continue to focus on energy. Oncolin Therapeutics Inc....
BioCentury | Jul 21, 2008
Company News

Oncolin scientific advisory board update

Oncolin Therapeutics Inc. (OTCBB:OCOL), Houston, Texas Business: Cancer Appointed: Waldemar Priebe, professor of medicinal chemistry at the University of Texas M. D. Anderson Cancer Center, as chairman WIR Staff cancer...
BioCentury | Jun 30, 2008
Company News

Oncolin scientific advisory board update

Oncolin Therapeutics Inc. (OTCBB:OCOL), Houston, Texas Business: Cancer Appointed: Daniel Von Hoff, CSO of US Oncology and Scottsdale Clinical Research Institute and a member of the National Cancer Advisory Board WIR Staff cancer...
BioCentury | Jun 16, 2008
Company News

Oncolin, University of Texas M. D. Anderson Cancer Center deal

...Oncolin will have exclusive rights to any resulting new patents. Further terms were not disclosed. Oncolin Therapeutics Inc....
BioCentury | May 12, 2008
Company News

Oncolin scientific advisory board update

Oncolin Therapeutics Inc. (OTCBB:OCOL), Houston, Texas Business: Cancer Appointed: Randall Johnson, an industry consultant WIR Staff...
BioCentury | Apr 21, 2008
Clinical News

Oncolin preclinical data

...improvements that were similar to Temodar monotherapy. Schering-Plough Corp. (NYSE:SGP, Kenilworth, N.J.) markets Temodar temozolomide. Oncolin Therapeutics Inc....
BioCentury | Mar 10, 2008
Company News

Oncolin scientific advisory board update

Oncolin Therapeutics Inc. (OTCBB:ELHI), Houston, Texas Business: Cancer Appointed: Sandra Silberman WIR Staff...
Items per page:
1 - 7 of 7